ANGO vs NBIX · rev $292.5M vs P/E 45, rev $2.36B
AngioDynamics Inc (ANGO) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
AngioDynamics Inc (ANGO) is a medical instruments & supplies company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ANGO revenue for 2025-05-31 was $292.5M. Net income was -$34.0M. Revenue was down 3.8% from 2024-05-31 to 2025-05-31. ANGO currently screens at market cap $378.5M.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
ANGO currently screens at market cap $378.5M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the ANGO and NBIX stock pages for the full models.
Not investment advice.